Completed PHASE1 INTERVENTIONAL 1-arm NCT01305512

Pharmacokinetic, Safety and Tolerability Study of SPARC1028

Sponsor: Sun Pharma Advanced Research Company Limited

Conditions Solid Tumor in Advanced Stage

Interventions SPARC1028

Updated 7 times since 2017 Last updated: May 2, 2019 Started: May 31, 2012 Primary completion: Jun 30, 2016 Completion: Aug 31, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01305512, this PHASE1 trial focuses on Solid Tumor in Advanced Stage and remains completed. Sponsored by Sun Pharma Advanced Research Company Limited, it has been updated 7 times since 2012, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2019 — Jan 2021 [monthly]

Completed PHASE1
Jun 2018 — Jun 2019 [monthly]

Completed PHASE1

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE1
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

May 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Sun Pharma Advanced Research Company Limited

Data source: Sun Pharma Advanced Research Company Limited

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Buffalo, United States